Bio-Techne Announces Release of GMP TcBuster Non-Viral Genome Engineering System

MINNEAPOLIS, Feb. 18, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of GMP Transposase mRNA for the TcBuster™ non-viral genome engineering system, supporting the development and manufacture of immune cell- and stem cell-based therapies.

The TcBuster System has been widely used by researchers to introduce large cargo genetic modifications in a range of cell types. The new GMP transposase will offer a clearer path to clinic for applications in gene edited cell therapies, such as CAR-T or TCR generation.

Non-viral TcBuster offers numerous benefits over traditional lentivirus-based engineering methods for cell therapy development. The natural transposase has been enhanced through protein engineering, resulting in a hyperactive enzyme. As a result, multiple genes can be delivered from a GMP transposon simultaneously while maintaining high editing efficiency and a de-risked insertional profile. By negating the need for viral clearance methods, the TcBuster system also significantly reduces both the time to market and cost requirements for cell therapy developers. Moreover, Bio-Techne has a strong and reliable supply chain for both RUO & GMP grade reagents, including innovative options for closed-system manufacturing, making it a dependable option for scaling from research to clinical and commercial stages.

"Our customers rely on us to help de-risk their cell therapy manufacturing programs and support their scale up to clinical trials and commercial manufacturing," said Will Geist, President Bio-Techne's Protein Science Segment. "Releasing a GMP version of our TcBuster non-viral genome engineering system marks a significant advance in meeting that goal, providing cell therapy developers with a powerful tool for efficient gene editing without the drawbacks of traditional viral delivery systems."

The TcBuster system is compatible with a range of cell types, including immune cells and stem cells, and can be used for a wide range of applications, including autologous CAR-T or TCR manufacturing, allogeneic NK therapies, and for engineering bioprocessing cell lines for therapeutic biologics production.

The GMP TcBuster transposase is available now online at www.bio-techne.com/tcbuster. For more information on the TcBuster non-viral genome engineering system, please visit our website or contact us directly.

About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com or follow the Company on social media at Facebook, LinkedIn, Twitter or YouTube.

About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com 
612-656-4416

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-release-of-gmp-tcbuster-non-viral-genome-engineering-system-302376063.html

SOURCE Bio-Techne Corporation